Perkovic, VladoVladoPerkovicBlackorby, AllisonAllisonBlackorbyCizman, BorutBorutCizmanCarroll, KevinKevinCarrollCobitz, Alexander R.Alexander R.CobitzDavies, RichRichDaviesDiMino, Tara L.Tara L.DiMinoJha, VivekanandVivekanandJhaJohansen, Kirsten L.Kirsten L.JohansenLopes, Renato D.Renato D.LopesKler, LataLataKlerMacdougall, Iain C.Iain C.MacdougallMcMurray, John J. V.John J. V.McMurrayMeadowcroft, Amy M.Amy M.MeadowcroftObrador, GregorioGregorioObradorSolomon, ScottScottSolomonTaft, LinLinTaftWanner, ChristophChristophWannerWaikar, Sushrut S.Sushrut S.WaikarWheeler, David C.David C.WheelerWiecek, AndrzejAndrzejWiecekSingh, Ajay K.Ajay K.Singh2022-11-242022-11-242021https://scripta.up.edu.mx/handle/20.500.12552/218510.1093/ndt/gfab318Background: Anaemia is common in chronic kidney disease (CKD) and assessment of the risks and benefits of new therapies is important. Methods: The Anaemia Study in CKD: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) trial includes adult patients with CKD Stages 3-5, not using erythropoiesis-stimulating agents (ESAs) with screening haemoglobin (Hb) 8-10 g/dL or receiving ESAs with screening Hb of 8-12 g/dL. Participants were randomized to daprodustat or darbepoetin alfa (1:1) in an open-label trial (steering committee- and sponsor-blinded), with blinded endpoint assessment. The co-primary endpoints are mean change in Hb between baseline and evaluation period (average over Weeks 28-52) and time to first adjudicated major adverse cardiovascular (CV) event. Baseline characteristics were compared with those of participants in similar anaemia trials. © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.enAnaemiaBaseline dataChronic kidney diseaseDaprodustatDarbepoetin alfaResource Types::text::journal::journal article